Peer-reviewed publications as of June 1, 2024: 100 original articles, letters and reviews; h-index: 20; i10-index: 38; total citations: 3,356 (Google Scholar statistics).

Asterisks (*) indicate equal author contributions / shared authorships.

2023

Bourgonje AR, van Goor H, Bakker SJL, Bilo HJG, Dullaart RPF, van Dijk PR. Serum levels of peroxiredoxin-4, a biomarker of oxidative stress, are associated with the development of nephropathy in patients with type 2 diabetes (Zodiac-65). Free Radic Biol Med 2023;212:186-190. doi: 10.1016/j.freeradbiomed.2023.12.025.

Geertsema S, Jansen BH, van Goor H, Dijkstra G, Faber KN, Bourgonje AR. Unsuitability of the Oxidation-Reduction Potential Measurement For Quantification of Fecal Redox Status in Inflammatory Bowel Disease. Biomedicines 2023;11(12):3107. doi: 10.3390/biomedicines11123107.

Versluis J, Bourgonje AR, Touw DJ, Meinderts JR, Prins JR, de Jong MFC, Mian P. Pharmacokinetics of Tacrolimus in Pregnant Solid-Organ Transplant Recipients: A Retrospective Study. J Clin Pharmacol 2024;64(4):428-436. doi: 10.1002/jcph.2393.

Bourgonje AR, Mian P. Identifying Phenotypic Determinants of Infliximab Target Concentrations in Inflammatory Bowel Disease: Towards Personalized Evidence-Based Dosing Regimens. Am J Gastroenterol 2023;118(12):2308-2309. doi: 10.14309/ajg.0000000000002365.

Loveikyte R, Bourgonje AR, van Goor H, Dijkstra G, van der Meulen-de Jong AE. The effect of iron therapy on oxidative stress and intestinal microbiota in inflammatory bowel diseases: A review on the conundrum. Redox Biol 2023;68:102950. doi: 10.1016/j.redox.2023.102950.

Bourgonje AR, Connelly MA, van Goor H, van Dijk PR, Dullaart RPF. Plasma Citrate Levels Are Associated with an Increased Risk of Cardiovascular Mortality in Patients with Type 2 Diabetes (Zodiac-64). J Clin Med 2023;12(20):6670. doi: 10.3390/jcm12206670.

Ghoti H, Zreid H, Ghoti I, Bourgonje AR, Diepstra A, van Goor H, Jeadi H, van Eijk LE, Weiss G. Clinical outcome and humoral immune responses of β-thalassemia major patients with severe iron overload to SARS-CoV-2 infection and vaccination: a prospective cohort study. EClinicalMedicine 2023;62:102096. doi: 10.1016/j.eclinm.2023.102096.

Geertsema S, Bourgonje AR, Fagundes RR, Gacesa R, Weersma RK, van Goor H, Mann GE, Dijkstra G, Faber KN. The NRF2/Keap1 pathway as therapeutic target in inflammatory bowel disease. Trends Mol Med 2023;S1471-4914(23)00158-2. doi: 10.1016/j.molmed.2023.07.008.

Otten AT, Dijkstra G, Visschedijk MC, Bourgonje AR. The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients. Inflamm Bowel Dis 2024;30(2):318-319. doi: 10.1093/ibd/izad144.

de Koning MSLY, Al-Ali L, Bourgonje AR, Westenbrink BD, Assa S, van Veldhuisen DJ, Lipsic E, van Goor H, van der Harst P. Associations of systemic oxidative stress with functional outcomes after ST-segment myocardial infarction. Int J Cardiol 2023;131214. doi: 10.1016/j.ijcard.2023.131214. 

Bourgonje AR, Connelly MA, van Goor H, van Dijk PR, Dullaart RPF. Both LDL and HDL particle concentrations associate positively with an increased risk of developing microvascular complications in patients with type 2 diabetes: lost protection by HDL (Zodiac-63). Cardiovasc Diabetol 2023;22(1):169. doi: 10.1186/s12933-023-01909-1.

Otten AT, van der Meulen HH, Steenhuis M, Loeff FC, Touw DJ, Kosterink JGW, Frijlink HW, Dijkstra G, Visschedijk MC, Bourgonje AR. Clinical Validation of a Capillary Blood Home-Based Self-Sampling Technique for Monitoring of Infliximab, Vedolizumab, and C-Reactive Protein Concentrations in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2024;30(3):325-335. doi: 10.1093/ibd/izad103.

Hollander EM, van Tuinen EL, Scholvinck EH, Bergman KA, Bourgonje AR, Gracchi V, Kneyber MCJ, Touw DJ, Mian P. Evaluation of Dosing Guidelines for Gentamicin in Neonates and Children. Antibiotics (Basel) 2023;12(5):810. doi: 10.3390/antibiotics12050810.

Dunning BJ, Bourgonje AR, Bulthuis MLC, Alexander J, Aaseth JO, Larsson A, van Goor H, Alehagen U. Selenium and coenzyme Q₁₀ improve the systemic redox status while reducing cardiovascular mortality in elderly population-based individuals. Free Radic Biol Med 2023;204:207-214. doi: 10.1016/j.freeradbiomed.2023.04.024.

Xu S, Li X, Zhang S, Qi C, Zhang Zm Ma R, Xiang L, Chen L, Zhu Y, Tang C, Bourgonje AR, Li M, He Y, Zeng S, Hu S, Feng R, Chen M. Oxidative stress gene expression, DNA methylation, and gut microbiota interaction trigger Crohn’s disease: A multi-omics Mendelian randomization study. BMC Med 2023;21(1):179. doi: 10.1186/s12916-023-02878-8.

Bourgonje AR^*, Andreu-Sánchez S^*, Vogl T, Hu S, Vich Vila A, Gacesa R, Leviatan S, Kurilshikov A, Klompus S, Kalka IN, van Dullemen HM, Weinberger A, Visschedijk MC, Festen EAM, Faber KN, Wijmenga C, Dijkstra G, Segal E, Fu J, Zhernakova A, Weersma RK. Phage-display immunoprecipitation sequencing of the antibody epitope repertoire in inflammatory bowel disease reveals distinct antibody signatures. Immunity 2023;56(6):1393-1409.e6. doi: 10.1016/j.immuni.2023.04.017.

Andreu-Sánchez S^*, Bourgonje AR^*, Vogl T, Kurilshikov A, Leviatan S, Ruiz Moreno AJ, Hu S, Sinha T, Vich Vila A, Klompus S, Kalka IN, de Leeuw K, Arends S, Jonkers IH, Withoff S, Brouwer E, Weinberger A, Wijmenga C, Segal E, Weersma RK, Fu J, Zhernakova A. Phage-display immunoprecipitation sequencing reveals that genetic, environmental, and intrinsic factors influence variation of human antibody epitope repertoires. Immunity 2023;56(6):1376-1392.e8. doi: 10.1016/j.immuni.2023.04.003.

Geertsema S, van Goor H, Dijkstra G, Faber KN, Bourgonje AR. Letter: disentangling the role of redox-active compounds in the development of inflammatory bowel diseases – moving towards causal associations. Aliment Pharmacol Ther 2023;57(9):1046-1047. doi: 10.1111/apt.17455.

de Koning MSLY, Emmens JE, Romero-Hernández E, Bourgonje AR, Assa S, Figarska SM, Cleland JGF, Samani NJ, Ng LL, Metra M, Filippatos GS, Lang CC, van Veldhuisen DJ, Anker SD, Dickstein K, Voors AA, Lipsic E, van Goor H, van der Harst P. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure. Clin Res Cardiol 2023;112(8):1056-1066. doi: 10.1007/s00392-023-02171-x.

van der Holst AM, Otten AT, van Renterghem ARPKM, Bourgonje AR, van Loo ES, van Praag EM, Dijkstra G, Buskens CJ, Stassen LPS. Temporary diverting stoma in therapy-refractory luminal colonic Crohn’s disease: an alternative to immediate colorectal resection? Colorectal Dis 2023;25(6):1176-1186. doi: 10.1111/codi.16552.

Bourgonje MF, Abdulle AE, Kieneker LM, Bulthuis MLC, la Bastide-van Gemert S, Mulder DJ, de Borst MH, Gansevoort RT, Bakker SJL, Gordijn SJ, van Goor H, Bourgonje AR. A Sex-Specific Comparative Analysis of Oxidative Stress Biomarkers Predicting the Risk of Cardiovascular Events and All-Cause Mortality in the General Population: A Prospective Cohort Study. Antioxidants 2023;12(3):690. doi: 10.3390/antiox12030690.

Otten AT, Peters V, Barth I, Stevens CL, Bourgonje AR, Frijlink HW, Harmsen HJM, Rehman A, Campmans-Kuijpers MJE, Dijkstra G. Effects of ileo-colonic delivered vitamin B₂, B₃, and C or the Groningen Anti-Inflammatory Diet on disease course and microbiome of patients with Crohn’s disease (VITA-GrAID study): a protocol for a randomized and partially blinded trial. BMJ Open 2023;13(3):e069654. doi: 10.1136/bmjopen-2022-069654.

Bourgonje AR, van Goor H, Faber KN, Dijkstra G. Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities. Clin Transl Gastroenterol 2023;14(7):e00579. doi: 10.14309/ctg.0000000000000579.

Bourgonje AR, Abdulle AE, Bourgonje MF, Kieneker LM, la Bastide-van Gemert S, Gordijn SJ, Hidden C, Nilsen T, Gansevoort RT, Mulder DJ, Dullaart RPF, de Borst MH, Bakker SJL, van Goor H. Plasma Neutrophil Gelatinase-Associated Lipocalin Associates with New-Onset Chronic Kidney Disease in the General Population. Biomolecules 2023;13(2):338. doi: 10.3390/biom13020338.

Borkent J, Ioannou M, Folkertsma T, Haarman BCM, van Goor H, Sommer IEC, Bourgonje AR. Systemic oxidative stress in recently diagnosed patients with schizophrenia spectrum disorders. Psychiatry Res 2023;321:115075. doi: 10.1016/j.psychres.2023.115075.

Geertsema S, Otten AT, Bouwknegt DG, Visschedijk MC, Bourgonje AR. Assessment of Fecal Glycosylated Mucins as Novel Biomarkers in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2023;29(3):e10-e11. doi: 10.1093/ibd/izac265.

Bourgonje AR, van der Vaart A, Gruppen EG, van Goor H, Bakker SJL, Connelly MA, van Dijk PR, Dullaart RPF. Plasma levels of GlycA, a pro-inflammatory glycoprotein biomarker, associate with an increased risk of microvascular complications in patients with type 2 diabetes (Zodiac-62). Endocrine 2023;80(2):312-316. doi: 10.1007/s12020-023-03319-5.

Loveikyte R^*, Bourgonje AR^*, van der Reijden JJ, Bulthuis MLC, Hawinkels LJAC, van Goor H, van der Meulen-de Jong AE, Dijkstra G. Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab. Inflamm Bowel Dis 2023;29(8):1272-1284. doi: 10.1093/ibd/izad010.

Feenstra L, Kutikhin AG, Shishkova DK, Buikema H, Zeper LW, Bourgonje AR, Krenning G, Hillebrands JL. Calciprotein Particles Induce Endothelial Dysfunction by Impairing Endothelial Nitric Oxide Metabolism. Arterioscler Thromb Vasc Biol 2023;43(3):443-455. doi: 10.1161/ATVBAHA.122.318420.

Bourgonje AR, Otten AT. The Risk of Developing Long COVID in Patients with Inflammatory Bowel Diseases: Do Immunosuppressive Drugs Matter? Clin Gastroenterol Hepatol 2023;21(7):1971-1972. doi: 10.1016/j.cgh.2022.12.030.

Bourgonje AR, Grochot-Przeczek A, Kloska D, Feelisch M, Cuadrado A, van Goor H. Personalized redox medicine in inflammatory bowel disease: emerging role of HIF1α and NRF2 as therapeutic targets. Redox Biol 2023;60:102603. doi: 10.1016/j.redox.2023.102603.